Neurocrine Biosciences Reports Q3 2026 Record Revenue and Raised INGREZZA Guidance
Neurocrine Biosciences (NBIX) reported strong third-quarter 2026 financial results, highlighted by total revenue of $1.1 billion, a 41% increase year-over-year. Growth was primarily driven by the company's diversified portfolio, including record sales for INGREZZA ($801 million) and significant triple-digit growth for CRESSINITY ($211 million). Non-GAAP diluted earnings per share rose to $3.29 from $2.17 in the prior year period. Management raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion. While the company faces anticipated mid-to-high single-digit pricing headwinds for INGREZZA in 2027, leadership expects double-digit volume growth to offset these pressures. The quarter also saw the impact of the Soleno Therapeutics acquisition through VYKAT XR sales, though management noted potential growth delays for VYKAT XR due to external safety report concerns.
Topics: EPS Beat Guidance Raise Pharmaceuticals Revenue Growth
Read the full article at Motley Fool
Part of the story Palantir Technologies Shares Decline Despite Record Q3 Revenue and Raised Guidance (16 articles)